



Latvijas Zinātnes
padome

Seminārs par Apvārsnis Eiropa tematisko kopu "Veselība" un misijas "Vēzis" atvērtajiem projektu konkursiem un ERA-Net "Transcan"



Līdzfinansē
Eiropas Savienība



Latvijas Zinātnes
padome



Latvijas Zinātnes
padome

TRANSCAN-3 ceturtais konkurss
“Combination therapies against cancer: new opportunities for translational research”

Uldis Berķis

13.06.2024



Latvijas Zinātnes
padome

TRANSCAN-3

- **ERA-NET vēža praktiskās izpētes jomā (Translational cancer research)**
- **Latvijas komandas salīdzinoši veiksmīgas, piem. TRANSCAN-3 katrā konkursā vismaz viena veiksmīga dalība, kopumā īstenojam 5 projektus**
- **Ceturtais konkurss plānots kā pēdējais, vienlaikus iet diskusijas ar Eiropas Komisiju par papildu finansējumu, lai rīkotu vēl vienu konkursu**
- **Apvārsnis Eiropa – vēža misija**
- **FP-10 – ļoti iespējama līdzfinansēta vēža partnerība**



Latvijas Zinātnes
padome

Tematikas 2024.g. konkursam

Aim 1. Development of new tumour derived models to test new drug combination therapies.

Aim 2. Design and development of high-throughput drug combination screening platforms to test new combination therapies.

Aim 3. Use of immunotherapy and radiotherapy combinations strategies to overcome drug resistance.

1. un 2. tēma ir preklīniskas, 3. tēmā – agrīni klīniskie pētījumi

Neatbalsta – II fāzes klīniskos pētījumus



Latvijas Zinātnes
padome

Konkursa informācija

**Pirmās kārtas projektu iesniegšanas termiņš – 2024. gada
5. jūlijs 12:00 CEST (13:00 pēc Latvijas laika)
Projektiem, kas iztur pirmo kārtu – otrās kārtas termiņš
2024. gada 29. novembris 12:00 CET**

Maksimālais projektu ilgums 3 gadi

**Latvija – underrepresented – var iekļaut kā 7. partneri
konsorcijā (standartā 3 - 6)**

Detāļas <https://transcan.eu/funding/calls/joint-call-jtc-2024-.kl>



Latvijas Zinātnes
padome

Jāņem vērā

Latvija atbalsta tikai pētniecību

Jaunie zinātnieki – ECR – 2-10 gadi pēc PhD. Konsorciā vismaz vienam grupas vadītājam (PI) jābūt ECR

Uzņēmumiem – ir jāpārbauda atbilstība pret visiem MK Noteikumu 259 noteiktajiem kritērijiem un konkursa atbilstības kritērijiem. Grūtībās nonākuši uzņēmumi tiek atzīti par neatbilstošiem dalībai konkursā

Max 2 dalībnieki no Latvijas projekta pieteikumā



Latvijas Zinātnes
padome

Valsts budžeta finansējuma apmērs

Latvijas dalībnieks projektā var saņemt līdz 100 000 EUR/ gadā

Ja projektā piedalās vairāki dalībnieki no Latvijas, katrs var saņemt valsts budžeta finansējumu līdz 100 000 EUR/gadā

Valsts budžeta finansējumu var saņemt:

- ✓ mazie un vidējie uzņēmumi,
- ✓ lielie uzņēmumi
- ✓ zinātniskās institūcijas – zinātniskie institūti, universitātes, augstskolas

Katrā konkursā paredzēts 600 000 EUR valsts finansējums. Ja konkursā ir vairāki virsslieksni sasnieguši projekti ar Latvijas dalībniekiem, valsts finansējumu var palielināt.



Latvijas Zinātnes
padome

Prasības pretendentiem

- ✓ Ir tieši atbildīgs par projekta sagatavošanu un izpildi
- ✓ Uzņēmumam ir jābūt privāto tiesību juridiskām personām un jābūt reģistrētām Latvijas Republikas Uzņēmumu reģistra Komercreģistrā
- ✓ Zinātniskajiem institūtiem, universitātēm ir jābūt reģistrētām Zinātnisko institūciju reģistrā
- ✓ Uzņēmumiem ir jāiesniedz pēdējo divu gadu finanšu pārskati (uzņēmumam ir jābūt reģistrētam vismaz pirms diviem gadiem)
- ✓ Zinātniskajiem institūtiem, universitātēm jāiesniedz publiskie pārskati par pēdējiem diviem pārskata gadiem
- ✓ Tam nedrīkst būt nodokļu parādu, ierosināts maksātnespējas process, nav sodīts vai jebkādi citi juridiski, t.sk., noteiktas sankcijas, vai finansiāli pārkāpumi, kas liedz saņemt valsts budžeta finansējumu, **nedrīkst būt GNU**
- ✓ Tas nesaņem citu publisko finansējumu (valsts budžeta, Eiropas Savienības finanšu avoti vai citi finanšu avoti) par tām pašām projekta attiecināmajām izmaksām un darbībām
- ✓ Uzņēmums, saņemot valsts atbalstu, nodala projekta attiecināmās izmaksas no pārējās uzņēmuma saimnieciskās darbības
- ✓ Zinātniskie institūti, universitātes, saņemot valsts līdzfinansējumu, nodala projekta



Latvijas Zinātnes
padome

Atbalsta intensitāte

Atbalsta intensitāte nepārsniedz:

- ✓ 50% no attiecināmajām izmaksām rūpniecisko pētījumu gadījumā
- ✓ 25% no attiecināmajām izmaksām eksperimentālās izstrādes gadījumā
- ✓ 50% no attiecināmajām izmaksām tehniski ekonomiskai priekšizpētei

Atbalsta intensitāti var palielināt, bet tā nedrīkst pārsniegt 80% no kopējām attiecināmajām izmaksām projektā:

- ✓ par 20% mazajiem uzņēmumiem
- ✓ par 10% vidējiem uzņēmumiem
- ✓ par 15%, ja projektā piedalās arī zinātniskie institūti, universitātes, ja tiek plānota rezultātu izplatīšana publikācijās, konferencēs vai arī ja projektā piedalās mazie vai vidējie uzņēmumi

Atbalsta intensitāte tiek piešķirta, ievērojot Eiropas Komisijas 2014.gada 17.jūnija Regulas Nr. 651/2014 4.iedaļas 25.pantu un Ministru kabineta 2015.gada 26.maija noteikumus Nr.259

Zinātniskie institūti, universitātes var saņemt līdz 100% valsts **līdzfinansējumu**



Latvijas Zinātnes
padome

Attiecināmās izmaksas

Projektu attiecināmās izmaksas attiecinā uz noteiktiem darbiem projektā, un tās ir šādas:

- ✓ Personāla izmaksas, komandējumi
- ✓ Izmaksas par instrumentiem un aprīkojumu, ciktāl tās ir attiecināmas uz projektu (amortizācija)
- ✓ Izmaksas par materiāliem, piederumiem
- ✓ Izmaksas par līgumpētījumiem (līdz 25% no projekta tiešajām izmaksām), patentiem, licencēm, kā arī citas izmaksas, kas ir nepieciešamas tiešo projekta mērķu sasniegšanai
- ✓ Netiešās izmaksas, kas radušās projekta darbības rezultātā:
 - ✓ Zinātniskajiem institūtiem, universitātēm līdz 25% no tiešajām izmaksām
 - ✓ Uzņēmumiem – faktiskās izmaksas, kas radušās projekta īstenošanas laikā, bet nepārsniedzot 25%



Latvijas Zinātnes
padome

Jautājumi





Latvijas Zinātnes
padome

Apvārsnis Eiropa veselības jomas aktualitātes

Jānis Ancāns, dr.biol.
Nacionālā kontaktpunkta vecākais eksperts
janis.ancans@lzp.gov.lv



Līdzfinansē
Eiropas Savienība



Nacionālais
attīstības plāns



Latvijas Zinātnes
padome


Apvārsnis Eiropa



Apvāršnis Eiropa tematiskā kopa «Veselība» un uzdevumu joma «Vēzis»

Health research funding under Horizon Europe

Budget in 2024



Cancer Mission calls 2023 vs. 2024

4 call topics

13 funded projects
(17 expected)

6 call topics


13 funded projects expected

Apvārsnis Eiropa tematiskās kopas «Veselība» dalībnieki

■ EU NET CONTRIBUTION, EUR

eCORDA data 10.04.2024.

*LATVIAN COUNCIL OF SCIENCE
(2887402 EUR)



Latvijas Universitāte «Veselības» kopā

EK finansējums	Projekta veids	Projekta akronīms
196 526 €	HORIZON-IA	PAIR
483 781 €	HORIZON-RIA	FAMILY
665 613 €	HORIZON-RIA	PRAESIIDIUM
53 375 €	HORIZON-CSA	CCI4EU
55 575 €	HORIZON-COFUND	PARC
755 250 €	HORIZON-RIA	AIDA
599 625 €	HORIZON-RIA	LUCIA



An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)



An Artificially Intelligent Diagnostic Assistant for gastric inflammation

Fact Sheet

Project description



An AI-based risk score for gastric cancer

Artificial intelligence (AI) is gradually being introduced into healthcare to improve disease risk assessment and predict clinical or therapy outcome. The EU-funded AIDA project aims to generate an AI-based risk score for gastric cancer, a disease that is usually detected at an advanced stage when little can be done in terms of treatment. Researchers will combine data from various sources to detect precancerous gastric inflammation and generate a risk score for gastric cancer. The approach will improve understanding of how gastric inflammation evolves into cancer and will help clinicians formulate a personalised treatment plan for preventing gastric cancer.

Hide the project objective

Objective

Most cases of gastric cancer (GC) are detected at a late stage, when patients have a median life expectancy of about a year. Diagnosing people at risk of developing GC at the pre-symptomatic stage, typically chronic gastric inflammation, could significantly improve the outlook.

Artificial intelligence (AI) can help clinicians make sense of their own data by automating much of the treatment and analysis, which require manual work and years of experience. But it can do more: it can bring together available data from various sources into a vast data lake and cross-correlate the data to derive a 'risk score' for gastric cancer

Project Information

AIDA
Grant agreement ID: 101095359

DOI
[10.3030/101095359](https://doi.org/10.3030/101095359)

EC signature date
5 December 2022

Start date
1 January 2023

End date
31 December 2026

Funded under
Health

Total cost
€ 6 334 803,75

EU contribution
€ 6 334 803,75



Coordinated by
FUNDACION PARA LA INVESTIGACION DEL
HOSPITAL CLINICO DE LA COMUNITAT
VALENCIANA, FUNDACION INCLIVA

Spain

<https://cordis.europa.eu/project/id/101095359>

An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)



<https://cordis.europa.eu/project/id/101095359>

An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)

Dear Participant Contact* of FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA in the project AIDA,

I am contacting you for the following reason: *

Your message...

My Name:

Janis ANCANS

My Email:

janis.ancans@lzp.gov.lv

I agree to use this Contact Request Form in accordance with the [Terms and Conditions](#) of the Funding & Tenders Portal electronic exchange system. I acknowledge, in particular, that the use of the Contact Form for commercial purpose or spamming is forbidden.

<https://cordis.europa.eu/project/id/101095359>

An Artificially Intelligent Diagnostic Assistant for gastric inflammation (AIDA)



Project ▼

Consortium

News & Events

About



Contact

Introducing AIDA

OVERVIEW

IMPLEMENTATION

<https://www.aidaeuproject.org/>

Understanding Lung Cancer related risk factors and their Impact (LUCIA)



Understanding Lung Cancer related risk factors and their Impact

Fact Sheet

Project description



A closer look at risk factors associated with lung cancer

Smoking tobacco is the biggest risk factor for lung cancer. However, it is not the only risk factor. For example, uranium (found in rocks and soils) is a cancer-causing agent. So is asbestos, arsenic, nickel, coal smoke, soot and diesel fumes. The EU-funded LUCIA project will focus on personal risk factors, external risk factors, and biological responses to those risk factors. It will develop a toolbox for analysis that will include databases, AI models, wearable devices, sensors and multi-omics. After identifying the effects of various risk factors, the project will study the molecular changes associated with these risk factors. The findings will be translated into policy recommendations and used in lung cancer screening programmes and digital diagnostics.

Hide the project objective

Objective

Lung Cancer (LC) is the biggest cancer killer worldwide, with five-year survival following diagnosis varying between 5% to 25%. Though tobacco smoking has long been recognized as the major risk factor for LC, many cases (incl.

Project Information

LUCIA

Grant agreement ID: 101096473

DOI

[10.3030/101096473](https://doi.org/10.3030/101096473)

EC signature date

5 December 2022

Start date

1 January 2023

End date

31 December 2026

Funded under

Health

Total cost

€ 13 516 869,00

EU contribution

€ 13 516 869,00



Coordinated by

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY

Israel

<https://cordis.europa.eu/project/id/101096473>

Understanding Lung Cancer related risk factors and their Impact (LUCIA)



<https://cordis.europa.eu/project/id/101096473>

LU Klīniskās un profilaktiskās medicīnas institūts

Nr.	Projekts	EK programma
1.	A-PATCH Autonomous Patch for Real-Time Detection of Infectious Disease	Horizon 2020
2.	PERSIST Patients-centered SurvivorShIp care plan after Cancer treatments based on Big Data and Artificial Intelligence	Horizon 2020
3.	VOGAS Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach	Horizon 2020
6.	EUROHELICAN Accelerating gastric cancer reduction in Europe through Helicobacter pylori eradication	EU4 Health
7.	AIDA An Artificially Intelligent Diagnostic Assistant for gastric inflammation	Horizon Europe
8.	LUCIA Understanding Lung Cancer related risk factors and their Impact	Horizon Europe
9.	TOGAS Towards Gastric Cancer Screening Implementation In The European Union	EU4 Health
10.	CCI4EU Comprehensive Cancer Infrastructure In Europe	Horizon Europe
11.	ECHoS Establishing of Cancer Mission Hubs: Networks and Synergies	Horizon Europe

LU Klīniskās un profilaktiskās medicīnas institūts

JAUNUMI



10.06.2024.

Profesors Mārcis Leja
Azerbaidžānā prezentē
starptautisko un Eiropas pieredzi
gastrointestinālo audzēju
skrīninga jomā

Sīkdatnes



29.05.2024.

LU KPMI pētnieki iepazīstina
Saeimas priekšsēdētāju ar
mākslīgā intelekta izmantošanu
medicīnā

<https://www.kpmi.lu.lv/>



28.05.2024.

Iepazīstina ar projekta AIDA norisi



Apvārsnis Eiropa 1. tematiskās kopas «Veselība» darba programma 2024. gadam



Latvijas Zinātnes padome



EN

Horizon Europe

Work Programme 2023-2024

4. Health

Darba programma:

https://research-and-innovation.ec.europa.eu/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe/cluster-1-health_en

Programmas ceļvedis:

https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf



(European Commission Decision C(2023) 2178 of 31 March 2023)

Apvārsnis Eiropa tematiskās kopas «Veselība» intervences jomas



Health throughout
the Life Course



Environmental and Social
Health Determinants



Non-communicable
and Rare Diseases



Infectious diseases



Tools, Technologies
and Digital Solutions
for Health and Care



Health Care Systems

Apvārsnis Eiropa tematiskās kopas «Veselība» intervences jomas

- Veselība visas dzīves laikā
- Neinfekcijas un retās slimības
- Veselības un aprūpes rīki, tehnoloģijas un digitāli risinājumi, tostarp personalizētā medicīna
- Vides un sociālie faktori veselībā
- Infekcijas slimības, tostarp ar nabadzību saistītas un novārtā atstātas slimības
- Veselības aprūpes sistēmas

D3: Tackling diseases and reducing disease burden

Publicēts: 25. aprīlis

Deadline: 25.septembris

Topic	Type of action, TRL	EU contribution per project (EUR million)	Number of projects to be funded
<u>HORIZON-HLTH-2024-DISEASE-09-01</u> : European Partnership: One Health Anti-Microbial Resistance	Cofund	100	1

«Veselība» 2024.g. papildus konkursi

Publicēts: 11. aprīlis

Iesniegšanas termiņš: 26. novembris

Topic	Type of action	EU contribution per project (EUR million)	Number of projects to be funded
<u>HORIZON-HLTH-2024-DISEASE-13-01</u> : Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)	RIA	3-4	5
<u>HORIZON-HLTH-2024-CARE-14-01</u> : Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems	PCP	3-5	3
<u>HORIZON-HLTH-2024-DISEASE-12-01</u> : European partnership for pandemic preparedness	Cofund	50	1

Tematiskās kopas «Veselība» informācijas diena

Horizon Europe info day: Cluster 1

This short information session aims to inform (potential) applicants about 3 new topics that have been added to the Cluster 1 'Health' work programme of 2024.

📅 28 May 2024
🕒 11:00 (GMT+03:00)



Overview Programme

Invite +

I'm interested ☆

Share this event on:



Programme

Filters - Clear all

Search a session

Search

Topics

- Circular Economy
- Civil Security
- Climate

Day 1

11:00 Introduction

📅 28 May 2024

🕒 11:00 - 11:10 (GMT+03:00)

Add to favourites ♡

Watch replay ▶

Show details

11:15 Topic 1 HORIZON-HLTH-2024-DISEASE-13-01 Presentation and Q&A

<https://research-innovation-community.ec.europa.eu/events/3clxegsRz1MMCZg2Onsstd/programme>

Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)

Expected outcome

- ... access to and use **specific guidelines to implement health interventions** that improve the availability of effective, equitable, efficient, integrated, patient-centred, safe, and timely care and the overall quality of life for people living with multiple long-term conditions including NCDs.
- ... access to **improved insights and evidence on how to decrease the fragmentation of care for patients living with multiple chronic conditions**, and ensure continuity of care across all stages of disease progression. They use this knowledge to design policies to reduce health inequities.
- ... **improved understanding how the proposed interventions could be adopted** in LMICs and/or disadvantaged populations of HICs setting, taking into account specific social, political, economic and cultural contexts.
- Communities and local stakeholders and authorities are **fully engaged in implementing and taking up interventions for management of multiple long-term conditions** in the context of NCDs and thus contribute to deliver better health.

Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)

Scope (1)

- ... **implementation research** for management of multiple long-term conditions in the context of NCDs (MLTC NCD) in LMICs and/or disadvantaged populations in HICs.
- ... focus on **one or more evidence-based interventions known to promote integrated management of multiple long-term conditions...**
- ... **justify the choice of intervention(s)** and provide **evidence of the intervention's effectiveness, acceptability, feasibility, and potential for long-term health and other impacts.**
- ... explore the implementation of proposed intervention(s) for **a selected study population(s) taking into account the unique social, political, economic, and cultural context(s)** in which the study will take place.
- The study population may include **patients with existing MLTC NCD**. The study population may also include **patients with chronic infectious disease(s) or a mixture of both.**
- ... an appropriate strategy for measuring **implementation research outcomes and real-world effectiveness outcomes and indicators.**

Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD)

Scope (2)

- ... address **health equity and the principles of Universal Health Coverage**.
- ... **a stakeholder engagement strategy**
- ... **implementation research outcomes to assess MLTC NCD**.
- Effective contribution of **social sciences and humanities** disciplines is required.
- ... **networking and joint activities** between all funded project will be strongly encouraged.

The following types of projects will NOT be funded: i) proposals focused on primary prevention of NCDs or other chronic conditions; ii) proposals with the primary aim of informing the development and/or selection of an intervention for a given context, where the implementation component will be explored in a future project; iii) epidemiological cohorts; iv) etiological work, mechanistic, or epidemiological research, unless an essential component of a focused study to develop implementation research approaches; v) clinical trials, validation studies, or intervention efficacy studies for a new or established pharmacological agent or behavioural intervention.

Konkursu specifiskie jautājumi

HORIZON-HLTH-2024-CARE-14-01: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems (PCP)

[Watch PCP explanation](#) for Topic; [Watch Presentation](#) of Topic; [Watch the Q&A](#) on this Topic

Question	Link to answer
1. How many PCP projects do you wish to support?	01:29:23
2. How does the fast-track procedure work? (number of PCP phases, etc.)	01:29:51
3. Do the buyers (as public bodies) have to follow also the own/national rules for procurements in the development of PCP project?	01:30:32
4. What makes a PCP grant different from a RIA or an IA grant?	01:31:19
5. Can suppliers be part of the consortium for the PCP topic?	01:32:27
6. In addition to the funding rules of Horizon Europe what other rules should potential applicants of the PCP be aware of?	01:33:14
7. Can only public procurers cooperate with private ones in the area of health and care?	01:34:31
8. Is it possible to foresee budget in the proposal to purchase the solution in the case of FastTrack PCP?	01:34:31
9. How many buyers have to be present in the proposal, how many countries?	01:35:39
10. Budget balance between coordination and procurement budget? (50/50, undefined?)	01:36:20
11. What are the EC expectations in terms of commitment (last paragraphs of the call text): Declaration of interest: what does this mean? From whom?	01:37:20
12. Does the coordinator have to be a public body?	01:38:14
13. Would a proposal including an innovative technology for the management of long-term NCDs, be suitable for this call?	01:38:48

<https://www.youtube.com/live/EN2kxn3Pk3k?t=790s>

<https://hnn30.healthncp.net/pdf/cluster-1-info-day-qa-2024-annex-1>

Horizontālie jautājumi

Question	Link to answer
1. Lump sum funding: When getting audited - do we need same records as before?	55:42
2. Lump-sum funding: who decides whether the work package is completed?	57:07
3. Blind evaluation: how to describe previous projects and work, if one is not allowed to name the organisations?	58:03
4. Blind evaluation: how to describe cohorts in the 1 st stage of proposals without giving information about partners involved?	59:04
5. Lump-sum funding: how is the approximation checked?	59:50
6. Project management: how do we split work program management along the reporting periods?	1:01:15
7. SSH involvement: What are such disciplines typical in health projects?	1:02:30
8. Lump-sum funding: How is the lump-sum funding applied to projects with associated partners, who are not receiving EU funding but contribute to work packages?	1:03:18
9. Lump-sum funding: Why do you not ask for detailed lump sum budgets during grant negotiation only from those consortia that receive the grant?	1:04:28
10. Lump-sum funding: Is there any pre-financing in lump-sum projects?	1:05:33
11. Blind evaluation: When the activity is very innovative and atypical, the blind application is hard to maintain or keep blind, since only one company is doing this. How can we do it in this case?	1:06:22
12. International cooperation: Are US partners eligible for the funding?	1:07:41
13. Blind evaluation: Currently the blind evaluation is applied in stage 1 only. Is there a long-term plan to have fully blind evaluation in the future?	1:08:22
14. Lump-sum funding: Should the project officer be informed about changes in budget lines?	1:09:07
15. Lump-sum funding: Does lump-sum funding apply to national agencies and partners involved in European Partnerships or to individual project consortia that apply to a call or both?	1:10:17
16. Gender balance: How is the female / male ratio considered? Is the prevalence of female scholars appreciated or discouraged?	1:10:53
17. Gender balance: When is the gender equality plan needed - at proposal submission or grant agreement preparation stage?	1:12:12
18. How to be a member of health cluster?	1:13:20

Q/A: <https://www.youtube.com/watch?v=ngF27Fw1E34#t=3m32s>

Misijas «Vēzis» plānotie konkursi 2024.g.



EUROPEAN UNION



Indicative Budget €123.97 m

Topics	Type of Action	Budgets (EUR million)	Expected EU contribution per project (EUR m)	Indicative number of projects expected to be funded
HORIZON-MISS-2024-CANCER-01-01 Use cases for UNCAN.eu research data platform	RIA	30	30	1
HORIZON-MISS-2024-CANCER-01-02 Support to the development of the UNCAN.eu research data platform and the ECPDC	CSA	3	3	1
HORIZON-MISS-2024-CANCER-01-03 Accessible & affordable risk predictor tests to advance early detection of heritable cancers in European regions	IA	35	10-12	3
HORIZON-MISS-2024-CANCER-01-04 Support a pragmatic clinical trial programme by cancer charities	CSA	3	3	1
HORIZON-MISS-2024-CANCER-01-05 Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer	RIA	36	4-6	6
HORIZON-MISS-2024-CANCER-01-06 An information portal for the European Cancer Patient Digital Centre	IA	12	12	1
Total		119		

Misija (uzdevumu joma) «Vēzis»

Visaptverošais mērķis ir līdz 2030. gadam ar profilakses un ārstēšanas palīdzību uzlabot dzīvi vairāk nekā 3 miljoniem cilvēku (ne tikai vēža slimniekiem, bet arī viņu ģimenēm)

Misija (uzdevumu joma) «Vēzis»

Četri galvenie mērķi:

- Izprast vēzi un tā riska faktorus
- Novērst to, kas ir novēršams
- Optimizēt diagnostiku un ārstēšanu
- Atbalstīt vēža slimnieku un vēzi pārcietušo cilvēku dzīves kvalitāti

Misijas «Vēzis» plānotie konkursi 2024.g.

Publicēts: 18 Aprīlis

Iesniegšanas termiņš: 18 Septembris

Topic	Type of action, TRL	EU contribution per project (EUR million)	Number of projects to be funded
<u>HORIZON-MISS-2024-CANCER-01-01</u> : Use cases for the UNCAN.eu research data platform	RIA	30	1
<u>HORIZON-MISS-2024-CANCER-01-02</u> : Support dialogue towards the development of national cancer data nodes	CSA	3	1
<u>HORIZON-MISS-2024-CANCER-01-03</u> : Accessible and affordable tests to advance early detection of heritable cancers in European regions	IA TRL 5-7	10-12	3
<u>HORIZON-MISS-2024-CANCER-01-04</u> : Support a pragmatic clinical trial programme by cancer charities	CSA	3	1
<u>HORIZON-MISS-2024-CANCER-01-05</u> : Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer	RIA	4-6	4
<u>HORIZON-MISS-2024-CANCER-01-06</u> : An information portal for the European Cancer Patient Digital Centre	IA TRL 5-7	12	1

Misijas «Vēzis» informācijas diena

EU Missions and cross-cutting activities info days

The event aims to inform potential applicants about the new topics included in the EU Missions and Cross-cutting Activities work programme 2024

📅 25 April 2024 - 26 April 2024

🕒 10:30 (GMT+03:00)

Overview Programme

Invite +

I'm interested ☆

Share this event on:

Twitter

Facebook

LinkedIn

Copy link

Programme

Filters - Clear all

Search a session

Search

Topics

Agriculture

Day 1

Day 2

10:30 **Cancer Mission**

📅 26 April 2024

🕒 10:30 - 12:30 (GMT+03:00)

Add to favourites ♥

Watch replay ▶

Show details

<https://research-innovation-community.ec.europa.eu/events/3WjiVunxm0t5j4zQLVax3Q/programme>

Misiju kontaktbiržas platforma



The banner features the European Union flag and logo in the top left corner. The main text reads "EU MISSIONS" in large white letters, followed by "Concrete solutions for our greatest challenges" in blue. Below this are five icons: a globe with a thermometer, a pink awareness ribbon, a blue building with a tree, a blue water drop, and a green plant with roots. The event dates "21 May 2024 - 22 May 2024" and the event title "Horizon Europe Missions Brokerage Event 2024" are displayed on a dark green background on the right. At the bottom right, the hashtags "#EUmissions" and "#HorizonEU" are visible.

[Home](#) [Timetable & How it works?](#) [IMPORTANT TO READ](#) [Plenary session](#) [FAQ](#) [Contact](#)

Don't miss the opportunity to get involved in the next Horizon Europe 2024 Missions proposals!

Register now

Open until 20 November 2024

<https://missions-horizon-europe-brokerage-2024.b2match.io/>

Misiju kontaktbiržas platforma

Cooperation Offer

631 Opportunities found

Search


PROJECT COOPERATION (631)

PROJECT COOPERATION May 31, 2024

Collaboration in proposals

Our focus for consortium building is on the topics indicated below. For any collaboration ideas, please send me a message.

Offering Expertise to Consortias +14


 **CHARIS GALANAKIS**
R&I DIRECTOR at GALANAKIS LABORATORIES L.P.
CHANIA, Greece

PROJECT COOPERATION May 30, 2024

Accessible and affordable tests to advance early detection of heritable canc...

Project Summary: Advancing Early Detection of Heritable Breast Cancer through a qPCR test revealing disease-specific molecular cues in blood. Project Overview: Heritable breast cancers are linked to gen...

+1


 **Jérémie THIBLET**
Chief Growth Officer at NeoVentures Biotechnology Europe
Villejuif, France

PROJECT COOPERATION May 28, 2024

Microfluidics research

We are group of researchers based in the Laboratory of Heat Equipment Research and Testing. Our my primary research areas include the flow structure and dynamics in microchannels with sudden expans...

Consortium/Coordinator seeks Partners +12

 **Paulius Vilkinis**
Senior researcher at Lithuanian Energy Institute
Kaunas, Lithuania

2025.g. konkursu tēmas (projekts)

<u>Health Cluster Destination</u>	<u>Topics for WP 2025</u>
D1.Staying healthy in a rapidly changing society	<ul style="list-style-type: none">• Integrated care strategies to improve the Quality of Life of people with disabilities (rehabilitation, supporting caregivers, incl. informal)
D2.Living and working in a health-promoting environment	<ul style="list-style-type: none">• The health impacts of exposure to pollution sources (focus on neurodegenerative diseases)• Bridging horizons in micro and <u>nanoplastics</u> and health research
D3.Tackling diseases and reducing disease burden	<ul style="list-style-type: none">• <u>Randomised</u> controlled trial to assess safety and efficacy of phage therapy for the treatment of antibiotic-resistance bacterial infections• Advancing innovative interventions for mental disorders• Development of monoclonal and polyclonal antibodies for the prevention and treatment of infectious diseases with epidemic potential

2025.g. konkursu tēmas (projekts)

D5.Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

- Enhancing cellular therapies with synthetic biology

- Advancing stem-cell secretome-based therapies

- Leveraging multimodal data to advance Generative AI applicability in biomedical research

- Application of Generative AI models in healthcare settings


D6.Maintaining an innovative, sustainable and globally competitive health industry

- Addressing the manufacturing hurdles for ATMPs

- Digitalisation of conformity assessment procedures of medical devices and in vitro diagnostic medical devices

- Multinational clinical studies of orphan devices and innovative devices for unmet clinical needs

Tematiskā kopa «Veselība» 2024.-2025.



Veselības NKP tīkla projekts HNN3.0

Events & Calls

Colour legend:
● Call ● Event

June 2024

Mon	Tue	Wed	Thu	Fri	Sat	Sun
27	28	29	30	31	1	2
EJP RD Final Conference	Info session - EU4Health Annual Work Programme 2024 Towards healthcare of the future	Call 3 - Tackling diseases (Single stage - 2024)	IMI impact on antimicrobial resistance			
	Horizon Europe InfoDay - Cluster 1, 2024 additional Calls	1+ Million Genomes: eustainability and uptake AI in support of Quantum-Enhanced Metabolic Magnetic Resonance Imaging Systems +4 more				
3	4	5	6	7	8	9
HNN 3.0 Coffee for Health NCPs - especially Newcomers! (June 2024)	Digital Europe Programme Info Day: European Digital Identity	EU Cancer Mission: First project cluster policy webinar - Understanding Cancer	5th Health NCP meeting			
10	11	12	13	14	15	16
EUCAIM Open Call: New Beneficiaries	EuroScience Open Forum 2024					
17	18	19	20	21	22	23
IHI Call 8 - Call Days						
24	25	26	27	28	29	30
1	2	3	4	5	6	7
			Combination therapies against cancer: new opportunities for translational research (JTC 2024)			

<https://www.healthncp.net/events-calls>







Veselības NKP tīkla projekts

Find open calls





Status:

● open ● closed ● forthcoming

Call identifier	Program	Deadline / Topic	Status	Calendar
<p>Call - Ensuring access to innovative, sustainable and high-quality health care (Single stage - 2024)</p> <p>https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-care-14-01</p>	<p>Cluster Health</p> 	<p>26.11.2024</p> <ul style="list-style-type: none"> HORIZON-HLTH-2024-CARE-14-01: Pre-commercial procurement for environmentally sustainable, climate neutral and circular health and care systems 	●	<p>iCal / Outlook</p> <p>Google</p> <p>Yahoo!</p>
<p>Call 2 - Partnerships in Health (2024)</p> <p>https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-disease-12-01</p>	<p>Cluster Health</p> 	<p>26.11.2024</p> <ul style="list-style-type: none"> HORIZON-HLTH-2024-DISEASE-12-01: European partnership for pandemic preparedness 	●	<p>iCal / Outlook</p> <p>Google</p> <p>Yahoo!</p>
<p>Call 2 - Tackling diseases (Single stage - 2024)</p> <p>https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-disease-13-01</p>	<p>Cluster Health</p> 	<p>26.11.2024</p> <ul style="list-style-type: none"> HORIZON-HLTH-2024-DISEASE-13-01: Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) 	●	<p>iCal / Outlook</p> <p>Google</p> <p>Yahoo!</p>
<p>Monoclonal antibody-based therapeutics for new variants of emerging viruses</p> <p>https://eic.ec.europa.eu/eic-2024-work-programme_en</p>	<p>EIC Accelerator</p> 	<p>03.10.2024</p> <p>Short applications: any time</p> <p>Full applications: 3 October 2024</p> <p>The Accelerator Challenges have been identified in areas where breakthrough technologies or game-changing innovations developed by start-ups or SMEs can have a major impact on EU objectives. In 2024, these objectives include a.o. the Health Emergency Response Authority (HERA).</p>	●	<p>iCal / Outlook</p> <p>Google</p> <p>Yahoo!</p>

<https://www.healthncp.net/find-open-calls>

Veselības NKP tīkla projekts

<p>Clone of Call - Research and Innovation actions supporting the implementation of the Mission on Cancer</p> <p>https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search?callCode=HORIZON-MISS-2024-CANCER-01</p>	<p>Mission Cancer</p> 	<p>18.09.2024</p> <ul style="list-style-type: none"> ▪ HORIZON-MISS-2024-CANCER-01-01: Use cases for the UNCAN.eu research data platform ▪ HORIZON-MISS-2024-CANCER-01-02: Support dialogue towards the development of national cancer data nodes ▪ HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions ▪ HORIZON-MISS-2024-CANCER-01-04: Support a pragmatic clinical trial programme by cancer charities ▪ HORIZON-MISS-2024-CANCER-01-05: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer ▪ HORIZON-MISS-2024-CANCER-01-06: HORIZON-MISS-2024-CANCER-01-04: An information portal for the European Cancer Patient Digital Centre 	<p>●</p>	<p><input type="button" value="iCal / Outlook"/></p> <p><input type="button" value="Google"/></p> <p><input type="button" value="Yahoo!"/></p>
<p>Combination therapies against cancer: new opportunities for translational research (JTC 2024)</p> <p>https://transcan.eu/funding/calls/?tag=21314</p>	<p>TRANSCAN</p> 	<p>05.07.2024 Pre-proposal</p> <p>The main purpose of this call will be design of patient preclinical models for combination therapies. Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients.</p>	<p>●</p>	<p><input type="button" value="iCal / Outlook"/></p> <p><input type="button" value="Google"/></p> <p><input type="button" value="Yahoo!"/></p>
<p>EUCAIM Open Call: New Beneficiaries</p> <p>https://cancerimage.eu/open-call/</p>	<p>EUCAIM</p> 	<p>10.06.2024</p> <p>The EUCAIM project is launching an open call for new beneficiaries to join the consortium.</p> <p>Objectives of the open call:</p> <ul style="list-style-type: none"> ▪ Onboard new cancer image data holders, increasing the geographic dimensions, data modalities or cancer targets ▪ Include new reliable AI algorithms trained on the cancer image data of the repository. 	<p>●</p>	<p><input type="button" value="iCal / Outlook"/></p> <p><input type="button" value="Google"/></p> <p><input type="button" value="Yahoo!"/></p>
<p>Call 3 - Tackling diseases (Single stage - 2024)</p> <p>https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2024-disease-17-01</p>	<p>Cluster Health</p> 	<p>30.05.2024</p> <ul style="list-style-type: none"> ▪ HORIZON-HLTH-2024-DISEASE-17-01: Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic preparedness 	<p>●</p>	<p><input type="button" value="iCal / Outlook"/></p> <p><input type="button" value="Google"/></p> <p><input type="button" value="Yahoo!"/></p>
<p>Supporting patients' access to their health data in the context of healthcare services for citizens across the EU</p>	<p>Digital Europe Programme</p>	<p>29.05.2024</p> <p>DIGITAL-2024-CLOUD-AI-06-HEALTHACCESS</p>	<p>●</p>	<p><input type="button" value="iCal / Outlook"/></p> <p><input type="button" value="Google"/></p>

<https://www.healthncp.net/find-open-calls>

Veselības NKP tīkla projekts

HNN 3.0 - Supporting Tools

Question & Answer (Q&A) Documents

Blind Evaluations in Horizon Europe - Q&A	⌵
InfoDay Cluster 1 "Health" - Q&A on Calls 2024	⌵
InfoDay Cluster 1 "Health" - Q&A on Calls 2023	⌵

Annotated Templates

Annotated Template - Information on Clinical Studies	⌵
--	---

Guiding Documents

Hop-on Toolkit	⌵
Factsheet - Health funding in EU4Health and Horizon Europe	⌵
Guidelines for Partner Search	⌵
Guidelines for Pitch Sessions for institutions from Widening Countries	⌵

Trainings / Webinars

Webinar on the Annotated Horizon Europe template 'Information on Clinical Studies'	⌵
Webinar on the Cancer Mission	⌵
Training on Evaluation process	⌵
Webinar on Proposal preparation and Proposal template in Horizon Europe	⌵

<https://www.healthncp.net/hnn-30-supporting-tools>



Latvijas Zinātnes
padome

APVĀRSNIS
EIROPA

#NKP

Jānis Ancāns
Nacionālā kontaktpunkta vecākais eksperts
mob. 26494422
janis.ancans@lzp.gov.lv



@apvarsnis



@Apvārsnis EU Latvijas Nacionālais
kontaktpunkts - HE NCP LV



Latvijas Zinātnes
padome

<https://www.lzp.gov.lv/lv/apvarsnis-eiropa>



Līdzfinansē
Eiropas Savienība



Latvijas Zinātnes
padome